Schweizerischer Nationalfonds / Fonds national suisse
Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence
plus
Actualités sur Medizin, Gesundheit
Schweizerischer Nationalfonds / Fonds national suisse
Innovations in ultrasound imaging improve breast cancer detection
Bern (ots) - A new ultrasound technique can help distinguish benign breast tumours from malignant ones. The technology was developed with support from the Swiss National Science Foundation. Ultrasound is one of the three main technologies used in medical imaging. It is more compact and affordable than nuclear magnetic resonance imaging (MRI) techniques, and safer than x-rays. But the images it produces are often difficult ...
plusCOMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for ...
plusNew Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...
plusUCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase
Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...
plusHovione Increases Production Capacity
Loures, Portugal (ots/PRNewswire) - 'One Site Shop' expands to respond to growing demands Hovione announces plan to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. This decision to expand follows growing customer demand since, one year ago ...
plus
Accuray Showcases Radiation Therapy Innovations Designed to Improve What's Possible for Patients at ASTRO 2018
Sunnyvale, California (ots/PRNewswire) - Building on its heritage of patient-first innovation, at this year's ASTRO (American Society for Radiation Oncology) Annual Meeting, Accuray Incorporated (NASDAQ: ARAY) will showcase radiation therapy solutions designed to enable clinicians to deliver truly personalized ...
plusMerck Inaugurates State-of-the-art Pharma Packaging Center in Darmstadt
Darmstadt, Germany (ots/PRNewswire) - - Expansion of the pharma manufacturing site at Merck's headquarters supports growth of current and future portfolio of pharma medicines - New building dedicated to the packaging and shipping of Merck's pharma medicines in more than 90 countries - EUR63 million investment in new packaging center is part of wider EUR1 billion ...
plusKazakhstan Hosted International Trade Union Conference on Chrysotile Asbestos
Moscow (ots/PRNewswire) - The International Trade Union Conference on Chrysotile Asbestos and Safety held in Kazakhstan. It was organised by the Industry Council of the Trade Union of Workers of the Construction Sector and Housing and Utilities Sector of Kazakhstan together with International Trade Union Alliance for Chrysotile. The conference held to discuss the ...
plusEuropean Society for Medical Oncology (ESMO)
Breast cancer patients use Twitter as a non-medical forum to share their experiences
Lugano/Munich (ots) - Twitter is a place where many cancer patients share and discuss their experiences, a study at the ESMO 2018 Congress reveals, based on analysis of the contents of over 6,000 tweets and retweets about breast cancer. The study was part of a larger, multidisciplinary project to observe the presence of different diseases on social media. The data ...
plusGlobal Survey and Documentary Film Expose Emotional Impact of Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.S media - Merck-sponsored survey developed in collaboration with IACO and Eurocarers reveals lifelong effects of caring for a loved one with MS - #MSInsideOut documentary film, executively produced by Shift.ms, provides artistic take on the experiences of those impacted by MS Merck, a leading science and ...
plusJanssen to highlight data from broad rheumatology portfolio at the 2018 Annual meeting of the American College of Rheumatology
Beerse, Belgium (ots/PRNewswire) - - One-year results from the Phase 2 study evaluating STELARA® (ustekinumab) in patients with active systemic lupus erythematosus featured in a plenary presentation - 13 presentations from approved and pipeline products provide real-world treatment and disease insights across ...
plus
Merck Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care
Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK ESMO Abstract # Avelumab: LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P; M7824 (TGF ?-trap/anti-PD-L1):1048O, 1463P, 1931P, 757P, 643P, 642P, 661P; tepotinib (MET kinase inhibitor): 1377O, 621PD, 698P; M6620: 1437P; M3814: 1845P; ...
plusGenerics Manufacturer Zentiva Starts Operations as Independent Company
Prague (ots/PRNewswire) - Today marks generics manufacturer Zentiva's first day as an independent organization, following completion of the company's previously announced divestment from Sanofi. Zentiva is headquartered in Prague, and the company - now backed by Advent International, one of the world's largest and most experienced global private equity investors - is ...
plusKyowa Kirin Presents Data at EORTC-Cutaneous Lymphoma Task Force Meeting Showing Significantly Improved Quality of Life for Patients With Mycosis Fungoides (MF) and Sézary Syndrome (SS) on Mogamulizumab
Tokyo (ots/PRNewswire) - First oral presentation of Quality of Life data from the phase III trial (MAVORIC), the largest randomised trial in MF and SS - the two most common types of Cutaneous T Cell Lymphoma[1] Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces that Quality of Life (QoL) data from the pivotal ...
plusInternational Diabetes Federation (IDF) Global Survey Reveals 2 in 3 People With Type 2 Diabetes Have Cardiovascular Disease Risk Factors and/or Have Experienced a Cardiovascular Event
Bagsværd, Denmark (ots/PRNewswire) - - Cardiovascular disease (CVD) is the leading cause of disability and death in people with type 2 diabetes[1] - Despite the high incidence, 1 in 4 people with type 2 diabetes have never discussed, or cannot recall discussing, CVD risk factors with a doctor[2] - First-ever global ...
plusVifor Pharma Wins 2018 Pharma 4.0 Award for Implementation of Augmented Reality System
Zurich (ots/PRNewswire) - Vifor Pharma Group today announced that the company and partner Goodly Innovations were awarded the 2018 Pharma 4.0 Award for the innovation of the year in manufacturing execution systems in the pharma industry. Presented on 24 September in Berlin, the purpose of the Pharma 4.0 Award is to recognise outstanding implementation in manufacturing ...
plusNew Phase 2 Data for Somapacitan Demonstrate Its Potential as an Efficacious Once-weekly Treatment for Childhood Growth Hormone Deficiency
Athens, Greece (ots/PRNewswire) - Somapacitan, a novel growth hormone derivative in development for once-weekly administration of growth hormone, matched the therapeutic benefits of once-daily Norditropin® (somatropin) in a phase 2 trial in children with growth hormone deficiency.[1] There are currently no approved ...
plus
Successful Launch of Merieux Participations 3, The New Growth Capital Fund of Merieux Equity Partners
Lyon, France (ots/PRNewswire) - Mérieux Equity Partners, a management company created by Mérieux Développement, announces the first closing of its third generation fund, Mérieux Participations 3, focusing on growth capital within the healthcare and nutrition sectors. (Logo: ...
plusMeMed Raises Over $70 Million to Advance Pioneering Point-Of-Care Platform and Immune-Based Test for Distinguishing Bacterial Versus Viral Infections
Haifa, Israel (ots/PRNewswire) - Round includes leading international investors, further solidifying MeMed's leadership in host-based diagnostics MeMed today announced the completion of a new round of financing totaling over $70 million, with participation from new and existing investors including Ping An Global ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Marie Heim-Vögtlin Prize 2018: Sara Montagner discovers the epigenetic secrets of mast cells
Bern (ots) - Epigenetic modifications of our DNA are a key aspect of the normal functioning of mast cells, which play an important role in immune reactions. Biologist Sara Montagner was able to demonstrate this in her work. She will receive this year's Marie Heim-Vögtlin Prize from the SNSF at the award ceremony in Bellinzona on 29 November 2018. Mast cells are white ...
plusPhilips Unveils Trilogy Evo and Growing Portfolio of Connected Solutions at ERS 2018
Amsterdam and Paris (ots/PRNewswire) - New portable ventilator builds on Philips respiratory clinical excellence to enhance transitional care coordination and collaboration At the European Respiratory Society (ERS) International Congress 2018 in Paris, France (September 15-19), Royal Philips (http://www.usa.philips.com/) (NYSE: PHG) (AEX: PHIA), a global leader in ...
plusBAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media - First positive Phase III immunotherapy trial in combination with a tyrosine kinase inhibitor (TKI) in any tumor type - Results significant in both PDL1+ and all-comer populations - Alliance plans to pursue a ...
plusflutiform® k-haler®, a Novel Treatment for Adolescents and Adults With Asthma, Now Available in Europe
Cambridge, England (ots/PRNewswire) - - flutiform k-haler is now available in Europe as an asthma treatment for adults and adolescents (aged 12 years and older)[1] - Research indicates that many patients make errors with their inhalers and this is associated with poor asthma control and increased exacerbations[2] - ...
plus
Hugo Petit Appointed CFO of OxThera
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held rare disease company today announced the appointment of Hugo Petit as its new Chief Financial Officer. Mr Petit previously served as the Chief Financial Officer of MedCap AB. While at MedCap, Hugo led the company's listing on Nasdaq Stockholm. Prior to joining MedCap, Hugo held several roles as Chief Financial Officer in small as well as medium ...
plusGerman Health Technology Assessment Body (IQWiG) Concludes Only Oncotype DX® Has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results
Geneva (ots/PRNewswire) - Updated Assessment of Breast Cancer Gene Expression Profiling Tests for Clinical Use in Germany Final German Federal Joint Committee (G-BA) Reimbursement Decision Expected by End of 2018 Genomic Health today announced the publication of an updated assessment ...
plusLeviticus Cardio Announces Successful Completion of Third Chronic Animal Study
Petah Tikva, Israel (ots/PRNewswire) - Leviticus Cardio, inventors of the versatile transcutaneous Coplanar Energy Transfer (CET) system for use with implanted left ventricular assist devices (LVADs), announces the successful completion of a 90-day preclinical chronic animal study to evaluate its CET technology in combination with a commercial heart pump. The trial was ...
plusOzempic® Consistently Reduced the Risk of Major Cardiovascular Events Across Type 2 Diabetes Populations at High CV Risk Regardless of Prior CV Events at Baseline
Munich (ots/PRNewswire) - Ozempic® (semaglutide) consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death (collectively termed major adverse cardiovascular events, MACE) in people with type 2 diabetes at high ...
plusCOMPASS Pathways Receives FDA Approval for Psilocybin Therapy Clinical Trial for Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received approval from the US Food and Drug Administration (FDA) for a clinical trial in psilocybin therapy for ...
plusGeneral Intermediates of Canada
General Intermediates of Canada, an Alberta Biotech Company, Receives Canadian Government Funding for Immuno-Oncology Project
Edmonton, Alberta (ots/PRNewswire) - Edmonton's GIC in pursuit of new immuno-oncology therapy Edmonton's General Intermediates of Canada Inc. (GIC) announced today that they have received conditional funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) related to ...
plus
Précédent24252627282930313233Suivant